Thymosin Alpha-1: A Comprehensive Drug Review Covering Hepatitis, Cancer, and Immune Enhancement | Research

The takeaway

Thymosin alpha-1 is a synthetic immune-modulating peptide in Phase III trials for hepatitis C and Phase II for hepatitis B, with additional evidence for cancer immunotherapy, HIV, and vaccine enhancement.

Phase III
Thymosin alpha-1 had reached Phase III clinical trials for hepatitis C, the most advanced stage of any thymic peptide drug development

What the researchers found

Thymosin alpha-1 demonstrates clinical efficacy in chronic hepatitis B and C (combined with interferon), with emerging evidence for cancer immunotherapy, HIV, and vaccine enhancement, showing excellent tolerability.

Why it matters

This review provides the complete clinical picture of thymosin alpha-1 — from mechanism to dosing to efficacy data — serving as the definitive reference for clinical decision-making.

How the study worked

Comprehensive drug review covering pharmacology (T-cell, NK cell, cytokine modulation), pharmacokinetics (SC dosing, 2-hour half-life), and clinical trial data across hepatitis, cancer, HIV, and vaccine applications.

What this study cannot tell us

Clinical data was still accumulating at time of review. Some applications had limited trial sizes. Long-term safety data was emerging. Head-to-head comparisons with newer therapies limited.

How to read the evidence

Moderate to strong evidence from a comprehensive review of Phase II/III clinical trial data across multiple indications.

When this study was published

Published in 2001. Thymosin alpha-1 (Zadaxin) is now approved in over 30 countries for hepatitis B and as an immune adjuvant.

The bigger picture

Thymosin alpha-1 represents one of the most clinically advanced peptide immunotherapies. Its broad immune enhancement with minimal side effects positions it as a versatile tool across infectious diseases and cancer.

Questions still open

Will larger Phase III trials confirm hepatitis C efficacy?
Can thymosin alpha-1 enhance checkpoint immunotherapy responses?
What is the optimal combination partner for each indication?

Common questions

What is thymosin alpha-1 used for?

It's approved in many countries for hepatitis B treatment and as an immune enhancer. It's also being studied for hepatitis C, cancer immunotherapy, HIV, and boosting vaccine responses. It works by strengthening T-cell and natural killer cell function.

Is it safe?

Thymosin alpha-1 has an excellent safety profile. Side effects are generally mild — occasional injection site reactions and rarely flu-like symptoms. It doesn't suppress the immune system like many other immune-modulating drugs.

Read the original research

Thymosin alpha-1.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 58(10), 879-85; quiz 886-8

View on PubMed ↗

Citation

Ancell, C D; Phipps, J; Young, L. (2001). Thymosin alpha-1.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 58(10), 879-85; quiz 886-8.